<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00941824</url>
  </required_header>
  <id_info>
    <org_study_id>0808100</org_study_id>
    <secondary_id>2009-010710-29</secondary_id>
    <nct_id>NCT00941824</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Evaluation of an Intensified and Decreasing Dosing Regimen of Mycophenolate Sodium in Combination With Tacrolimus Post Kidney Transplant: The Myfortic Study</brief_title>
  <official_title>Pharmacokinetic Evaluation of an Intensified and Decreasing Dosing Regimen of Mycophenolate Sodium in Combination With Tacrolimus During the First 3 Months Post Kidney Transplant (the myFORTic Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mycophenolate acid (MPA) has been developed and approved in combination with cyclosporine and&#xD;
      has been used in kidney transplantation for more than a decade. At present, combination of&#xD;
      tacrolimus and mycophenolate acid tends to be considered as the standard of care for&#xD;
      maintenance immunosuppression in kidney transplantation. Mainly due to a different effect on&#xD;
      the entero-hepatic recycling pathway, cyclosporine and tacrolimus differently interfere with&#xD;
      MPA clearance. When used with tacrolimus, MPA dosage has thus to be adjusted and cannot be&#xD;
      extrapolated from what is recommended for a cyclosporine-based treatment. However, there is&#xD;
      currently no clear guideline for MPA dosing when this drug is used in combination with&#xD;
      tacrolimus. This is potentially detrimental for patients since under-or overexposure of MPA&#xD;
      has been clinically linked to the outcome of transplantation.&#xD;
&#xD;
      The purpose of this study is to pharmacologically validate an original MPA dosing regimen in&#xD;
      combination with tacrolimus within the three months post-kidney transplant. This regimen&#xD;
      consists in an intensified dosing of mycophenolate sodium during the earliest period of&#xD;
      transplantation in order to rapidly reach the appropriate MPA blood exposure followed by a&#xD;
      gradual decrease in dose in order to prevent MPA overexposure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUC0 - 12 hours) of the MPA and its métabolites MPAG and Ac-MPAG</measure>
    <time_frame>at Day 2, Day 7, Day 15, Month 1, Month 3</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Kidney Transplantation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophénolate acid</intervention_name>
    <description>Day 0 to Day 7, 720 mg twice daily&#xD;
Day 8 to Day 30, 540 mg twice daily&#xD;
Day 30 to Day 90, 360 mg twice daily</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt;18 years&#xD;
&#xD;
          -  Renal transplant from a dead or alive donor.&#xD;
&#xD;
          -  Patients treated by initial quadritherapy with basiliximab, tacrolimus, steroid et&#xD;
             mycophenolate sodic&#xD;
&#xD;
          -  ΒHCG pregnancy test negative at the initiation of Myfortic ®&#xD;
&#xD;
          -  Effective contraception during treatment and up to 6 weeks after treatment with&#xD;
             Myfortic ®&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient at high risk of rejection of a transplant&#xD;
&#xD;
          -  IMC &gt; ou = 30&#xD;
&#xD;
          -  Platelets &lt; 75000 / mm3 and/or neutrophils &lt; 1500 / mm3 and/or leukocytes &lt; 2500/ mm3&#xD;
             and/or hemoglobin &lt; 6 g/dL.&#xD;
&#xD;
          -  Patient requiring a anti-CMV prophylaxis by valganciclovir.&#xD;
&#xD;
          -  Pregnancy or breast feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe Mariat, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT-ETIENNE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Departement of Nephrology CHU Saint-Etienne</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>July 9, 2009</study_first_submitted>
  <study_first_submitted_qc>July 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2009</study_first_posted>
  <last_update_submitted>March 24, 2010</last_update_submitted>
  <last_update_submitted_qc>March 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Clément Caillaux,</name_title>
    <organization>CHU SAINT-ETIENNE</organization>
  </responsible_party>
  <keyword>pharmacokinetic</keyword>
  <keyword>mycophénolate acid</keyword>
  <keyword>kidney transplantation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

